Related Experiment Video
Updated: May 22, 2026

Probiotic Studies in Neonatal Mice Using Gavage
Published on: January 27, 2019
Do oral probiotics affect growth and neurodevelopmental outcomes in very low-birth-weight preterm infants?
Fatma Nur Sari1, Zeynep Eras, Evrim Alyamac Dizdar
1Neonatal Intensive Care Unit, Zekai Tahir Burak Maternity and Teaching Hospital, Ankara, Turkey. fatmanurselek@yahoo.com
Insights
Oral probiotics given to very low-birth-weight (VLBW) preterm infants to prevent necrotizing enterocolitis (NEC) did not impact growth or neurodevelopmental outcomes by 18 to 22 months corrected age.
Area of Science:
- Neonatal research
- Pediatric nutrition
- Developmental pediatrics
Background:
- Necrotizing enterocolitis (NEC) is a serious condition affecting very low-birth-weight (VLBW) preterm infants.
- Oral probiotics are explored as a preventative measure for NEC.
- Long-term effects of probiotic supplementation on VLBW infants require evaluation.
Purpose of the Study:
- To assess the impact of oral probiotics on growth and neurodevelopment in VLBW preterm infants.
- To determine if probiotic supplementation influences neurodevelopmental impairment at 18 to 22 months corrected age.
- To evaluate the efficacy of early oral probiotic administration for NEC prevention and its long-term outcomes.
Main Methods:
- Prospective follow-up of VLBW infants from a randomized controlled trial.
- Growth parameters (weight, length, head circumference) were measured.
- Cognitive and neuromotor development assessed using Bayley Scales of Infant Development II.
- Sensory and neurological performance evaluated using standard techniques.
Main Results:
- 174 VLBW infants (86 probiotics, 88 control) were evaluated at 18-22 months corrected age.
- No significant differences observed in growth parameters between probiotic and control groups.
- No significant differences found in cognitive, neuromotor, sensory, or neurological outcomes.
Conclusions:
- Early oral probiotic administration to VLBW infants for NEC prevention did not alter growth outcomes.
- Probiotic supplementation did not affect neuromotor, neurosensory, or cognitive development at 18-22 months corrected age.
- Findings suggest no long-term benefit of this probiotic regimen on neurodevelopmental trajectories in VLBW infants.
Objective:
To evaluate the growth and neurodevelopment outcomes of very low-birth-weight (VLBW) preterm infants supplemented with oral probiotics for the prevention of necrotizing enterocolitis (NEC).
Study Design:
This prospective follow-up study was conducted in a cohort of VLBW preterm infants enrolled in a randomized controlled clinical trial to evaluate the efficacy of oral probiotics for the prevention of NEC. Growth outcomes included weight, length, and head circumference. Cognitive and neuromotor development were assessed by using the Bayley Scales of Infant Development II. Sensory and neurological performance was evaluated by standard techniques. The primary outcome was neurodevelopmental impairment at 18 to 22 months' corrected age.
Results:
A total of 221 infants completed the trial protocol. Of the 208 infants eligible for follow-up, 174 infants (86 in the probiotics group and 88 in the control group) were evaluated. There was no significant difference in growth and neurodevelopmental outcomes between the two groups.
Conclusion:
Oral probiotic administered to VLBW infants to reduce the incidence and severity of NEC started with the first feed did not affect growth, neuromotor, neurosensory, and cognitive outcomes at 18 to 22 months' corrected age.
More Related Videos
Related Concept Videos
Development of the Oral Microbiota
Development of Human Microbiota
Gut-Brain Axis
Probiotics
The Oral Microbiota
Introduction to the Human Microbiota

